
The Phase 3 study met its primary endpoint, but survival data were immature and the companies said the potential benefit may be limited.
BioNTech and DualityBio said their Phase 3 DYNASTY-Breast02 trial met its primary endpoint, showing a statistically significant but modest improvement in progression-free survival with trastuzumab pamirtecan versus investigator-selected chemotherapy. The study involved chemotherapy-naïve patients with HR+/HER2-low metastatic breast cancer whose disease had progressed on endocrine therapy.
At an interim analysis, overall-survival data were not mature. The companies reported a higher rate of interstitial lung disease than in earlier trials; most cases were Grade 1 or 2, while severe and fatal events occurred in a small proportion.
The companies said data available at the cutoff suggest the potential benefit would be limited in the context of current treatment options. They will discuss the data and determine next steps.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.